Corbaux P, Maillet D, Boespflug M, et al. - Researchers examined how age affects clinical outcomes and tolerance of immune checkpoint inhibitors (ICIs) in a real-life setting. In this retrospective multicentric series, the inclusion of 410 patients, who were receiving a single-agent ICI (cytotoxic T-lymphocyte-associated protein 4 or programmed death(ligand)1 inhibitors) for the standard treatment of locally advanced or metastatic cancer, was done. Lung cancer (n = 304, 74%), melanoma (n = 79, 19%) and urologic cancer (n = 27, 7%) were the primary tumour types. Elderly receiving ICIs exhibited long-term outcomes similar to those observed among younger patients with no increased immune-related toxicity. These findings support ICI therapy as an acceptable option for the elderly with advanced cancer.